CD274 and non-small cell lung carcinoma: MER4 HERVs have also been proposed as novel biomarkers for the response to immune checkpoint inhibitors (ICI), which, currently, are becoming the standard first-line treatment of advanced NSCLC for patients with high PD-L1 expression [11].